Search research articles
Contact Us
Filters
Showing results (81-90 of 101) with videos related to
Page
of 11
Sort By:
Blood
|
February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Blood
|
August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
Leukemia & Lymphoma
|
November 9, 2016
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
Heidi D Finnes, Kari G Chaffee, Timothy G Call, et al.
The Lancet. Haematology
|
September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Blood
|
July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S Siegel, Thomas Martin, Michael Wang, et al.
Haematologica
|
December 4, 2025
Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia
Karan Chohan, Jonas Paludo, Surendra Dasari, et al.
Blood
|
July 5, 2024
Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation
Karan Chohan, Jonas Paludo, Surendra Dasari, et al.
Leukemia & Lymphoma
|
August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Graeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group
Meletios A Dimopoulos, Evangelos Terpos, Asher Chanan-Khan, et al.
The Lancet. Haematology
|
July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 101) with videos related to
Sort By:
Page
of 11
Blood
|
February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Blood
|
August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
Leukemia & Lymphoma
|
November 9, 2016
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
Heidi D Finnes, Kari G Chaffee, Timothy G Call, et al.
The Lancet. Haematology
|
September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Blood
|
July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S Siegel, Thomas Martin, Michael Wang, et al.
Haematologica
|
December 4, 2025
Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia
Karan Chohan, Jonas Paludo, Surendra Dasari, et al.
Blood
|
July 5, 2024
Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation
Karan Chohan, Jonas Paludo, Surendra Dasari, et al.
Leukemia & Lymphoma
|
August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Graeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group
Meletios A Dimopoulos, Evangelos Terpos, Asher Chanan-Khan, et al.
The Lancet. Haematology
|
July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Page
of 11